Welcome to our dedicated page for Fulgent Genetics SEC filings (Ticker: FLGT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fulgent Genetics, Inc. (NASDAQ: FLGT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Fulgent is a technology-based company with a laboratory services business and a therapeutic development business, and its SEC reports offer detailed information on both areas. Investors can review annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K to understand how the company presents its financial condition, results of operations, and material events.
Fulgent’s earnings-related 8-K filings reference press releases that discuss revenue, core revenue, GAAP and non-GAAP income or loss, gross profit and margin, and adjusted EBITDA. These filings also describe how the company defines and reconciles non-GAAP measures to the most directly comparable GAAP metrics, and how management uses these measures to evaluate performance. For those analyzing FLGT stock, these documents are a primary source for understanding trends in the laboratory services and therapeutic development segments, as well as the company’s cash position and stock repurchase activity.
In addition to financial results, Fulgent uses Form 8-K to report other significant developments, such as preliminary clinical data from its oncology programs. For example, the company has filed an 8-K to furnish a press release describing preliminary data from a phase 2 trial of FID-007 in combination with cetuximab in recurrent or metastatic head and neck squamous cell carcinoma. Such filings provide context on the progress and risk profile of its therapeutic development pipeline.
On this page, users can track FLGT filings in near real time as they are made available through EDGAR. Stock Titan’s tools surface key forms such as 10-K for annual overviews, 10-Q for quarterly updates, and 8-K for material events, with AI-powered summaries that help explain complex sections and highlight important points. For those interested in governance, compensation, or potential insider activity, related SEC documents and forms can also be reviewed alongside the company’s broader disclosure record.
Fulgent Genetics (FLGT) Q2-25 10-Q highlights
- Revenue: $81.8 m, up 15% YoY; 1H-25 revenue $155.3 m (+15%). Precision Diagnostics remains the largest line ($47.3 m, 58%).
- Gross margin: 42.1% vs 37.3% prior-year as cost discipline in laboratory services offsets mix shift.
- Operating loss: –$19.7 m (vs –$18.9 m). Operating expenses rose 19% to $54.1 m on higher G&A (+24%) and marketing spend (+43%).
- Net loss attributable to shareholders: –$19.0 m (EPS –$0.62) vs –$8.7 m (–$0.29). 1H-25 EPS –$0.99.
- Impairment: $9.9 m write-down of Helio Genomics investment drove other expense; without it, other income was $8.1 m interest.
- Cash & investments: $777 m (cash + marketable securities) with $87.9 m cash vs $55.1 m YE-24. Long-term securities declined $86 m as durations shortened; total assets $1.2 bn.
- Operating cash flow: –$34.6 m vs +$11.6 m prior year, due mainly to $33 m federal tax payments and higher receivables.
- Share activity: Repurchased $13.9 m stock YTD; share count 30.6 m.
- Customer concentration: One institutional customer accounted for 22% of Q2 revenue and 29% of receivables.
- Regulatory matters: DOJ CIDs on lab billing and HRSA audit remain open; SEC investigation closed with no action (previous $1 m accrual reversed).
Outlook: Management did not provide forward guidance in the filing. Revenue growth persists but profitability deteriorated due to higher opex and one-time impairment; cash position remains strong.
Fulgent Genetics (FLGT) filed a Form 4 showing that CFO & Treasurer Paul Kim had 2,743 common shares withheld on 07/26/2025 to cover taxes upon the vesting of RSUs tied to the 2022 Fulgent Pharma merger. The transaction was coded “F,” meaning it was an automatic, non-discretionary share surrender for tax withholding, not an open-market sale. The shares were valued at an implied $18.37 each (company-supplied price).
After the withholding, Kim directly owns 339,828 shares, so his economic exposure fell by <1 %. No derivative securities were exercised or disposed of, and no cash changed hands. Because the disposition is routine and immaterial relative to Kim’s total stake, the filing is largely neutral for investors and does not alter the company’s fundamental outlook.